Table 3 Subgroup analyses on the primary outcome (death due to acute pancreatitis)

1

High-quality

6

[31, 34, 35, 37, 46, 47]

No significant

Moderate

2

Aprotinin

11

[27–29, 31–37, 41]

No significant

Low

3

Gabexate mesilate

6

[42–44, 46, 47, 49]

No significant

Low to moderate

4

Gabexate mesilate daily administrated dosage>900mg

5

[42, 44, 46, 47, 49]

No significant

Low to moderate

5

Gabexate mesilate daily administrated dosage>1500mg

2

[47, 49]

No significant

Low to moderate

6

Trials with CMR≦0.10

7

[29, 31–33, 37, 42, 46]

No significant

Low to moderate

7

Trials with CMR>0.10

10

[27, 28, 34–36, 41, 43, 46, 47, 49]

No significant

Low to moderate

8

Trials with CMR>0.20

2

[34, 49]

No significant

Low to moderate

9

Trials with industrial support

9

[27, 29, 31, 34, 35, 37, 41–43]

No significant

Low to moderate

10

Trials with industrial support

8

[28, 32, 33, 36, 44, 46]

No significant

Low to moderate